文献速递血栓与止血

血友病患者接受大型骨科手术后的术后出血并发症:一项前瞻性多中心观察性研究

Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: A prospective multicenter observational study.
PubMed 文献 · J Thromb Haemost · 2022-02-08

这项前瞻性多中心观察性队列研究纳入131例接受全髋或全膝关节置换术的血友病患者,评估术后大出血发生率。39例(29.8%)发生大出血,全髋置换组为46%、全膝置换组为25%。全髋置换、存在抑制物、超重或肥胖、未使用抗纤溶药物与出血风险升高相关;连续输注凝血因子和药物性血栓预防与出血风险无关。

要点

  • 131例手术中39例(29.8%)发生大出血,全髋置换46%、全膝置换25%。
  • 全髋置换较全膝置换大出血风险升高(OR 2.50,p = .05)。
  • 存在抑制物、超重或肥胖、未使用抗纤溶药物与出血风险升高相关。

核心结论

  • 尽管进行了凝血因子替代治疗,血友病患者接受全髋或全膝关节置换术后出血风险仍然较高。
  • 使用抗纤溶药物与出血风险降低相关。

研究设计与样本

  • 多中心、前瞻性、观察性队列研究。
  • 纳入年龄≥18岁、任何严重程度的血友病患者,接受全髋或全膝关节置换术。
  • 共131例手术(98例全膝置换、33例全髋置换)。
  • 临床决策由治疗医生根据当地诊疗标准自行决定,临床数据前瞻性记录。

主要发现

  • 131例手术中39例(29.8%)发生大出血,全髋置换组为46%、全膝置换组为25%。
  • 全髋置换较全膝置换大出血风险升高(OR 2.50,p = .05)。
  • 存在抑制物者大出血风险升高(OR 4.29,p = .04)。
  • 与正常体重指数相比,超重者大出血风险升高(OR 4.49,p < .01),肥胖者大出血风险升高(OR 6.09,p < .01)。
  • 未使用抗纤溶药物者大出血风险升高(OR 3.00,p = .03)。

关键数值与推荐

  • 大出血定义为关键部位出血、任何24小时内血红蛋白下降≥2 g/dl或输注≥2单位浓缩红细胞。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Persons with hemophilia (PWH) are at risk for chronic hemophilic arthropathy (HA). Joint replacement surgery may be used to relieve intractable pain and/or restore joint function. OBJECTIVES: This multicenter, prospective, observational cohort study evaluated the rate of bleeding during the postoperative period after total hip (THA) or knee arthroplasty (TKA). PATIENTS/METHODS: We included PWH of any severity ≥18 years of age who were undergoing THA or TKA. Clinical decisions were made at the discretion of the treating physician according to local standards of care. Clinical data were prospectively recorded. Major bleeding was defined as bleeding in a critical site, bleeding that resulted in either a 2 g/dl or greater decrease in hemoglobin during any 24-h period, or transfusion of two or more units of packed red blood cells. RESULTS: One hundred thirty-one procedures (98 TKA and 33 THA) were performed, 39 (29.8%) of which were complicated by major bleeding, including 46% of THA and 25% of TKA. The risk of major bleeding was increased in THA compared to TKA (OR 2.50, p = .05), and by the presence of an inhibitor (OR 4.29, p = .04), increased BMI (OR 4.49 and 6.09 for overweight and obese, respectively, compared to normal BMI, each p < .01), and non-use of an antifibrinolytic medication (OR 3.00, p = .03). Neither continuous clotting factor infusion (versus bolus infusion) nor pharmacologic thromboprophylaxis were associated with bleeding risk. CONCLUSIONS: The bleeding risk remains substantial after THA and TKA in PWH, despite factor replacement. Use of antifibrinolytic medications is associated with decreased risk.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Kleiboer B, Layer MA, Cafuir LA, et al. Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: A prospective multicenter observational study. J Thromb Haemost. 2022. PMID: 35080347. doi:10.1111/jth.15654

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。